Karyopharm bags a $193M Asian deal for se­linex­or and fol­lowup drug, shares jump

Karyopharm Ther­a­peu­tics $KP­TI has inked a re­gion­al Asian deal for its late-stage can­cer ther­a­py se­linex­or and a fol­low-up com­pound it has in the pipeline. Ono is pay­ing $22.3 mil­lion up­front to grab de­vel­op­ment and com­mer­cial rights to the two ther­a­pies for a slate of coun­tries that in­cludes Japan, South Ko­rea and Hong Kong. Ono is al­so on the hook for up to $170.7 mil­lion in mile­stones.

Karyopharm shares jumped 12% on the news.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.